What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)

Contentti, Edgar Carnero; Pablo, Lopez; Pettinicchi, Juan Pablo; Pappolla, Agustín; Míguez, Jimena; Patrucco, Liliana; Cristiano, Edgardo; Vrech, Cárlos; Tkachuk, Verónica; Liwacki, Susana; Correale, Jorge; Marrodán, Mariano; Gaitán, María I.; Fiol, Marcela; Negrotto, Laura; Ysrraelit, María Célica; Burgos, Marcos; Leguizamón, Felisa; Tavolini, Darío; Deri, Norma; Balbuena, María Eugenia; Mainella, Carolina; Luetic, Geraldine; Blaya, Patricio; Hryb, Javier; Menichini, María Laura; Pinheiro, Amelia Alvez; Nofal, Pedro; Zanga, Gisela; Barboza, Andrés; Martos, Iván; Lázaro, Luciana; Alonso, Ricardo; Silva, Emanuel; Bestoso, Santiago; Fracaro, María Eugenia; Carrá, Adriana; Garcea, Orlando; Liguori, Nora Fernández; Serena, Marina Alonso; Caride, Alejandro; Rojas, Juan Ignacio

doi:10.1016/j.msard.2021.102742

Cited by 16 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 , 47 Seronegative patients are often a heterogeneous group of patients that could impact on the results. Although MOG-ab status in AQP4-ab-negative patients was published recently (performed in 53.7% [36/67] of seronegative NMOSD cohort) for this registry, 10 it is worth mentioning that we do not know how many seronegative patients were tested for MOG-ab in this sample. All MOG-AD patients were tested for AQP4-ab and they were all negatives.…”

Section: Discussionmentioning

confidence: 87%

“…In this study based on data from the RelevarEM registry, 10 , 11 , 14 we evaluated 262 attacks and 270 therapeutic interventions in 131 NMOSD and MOG-AD patients followed and treated in Argentina. Neurologists registering patients in RelevarEM, were from every part of the country, ensuring a representative national sample of patients.…”

Section: Discussionmentioning

confidence: 99%

“… 8 Between 33% and 42% of MOG-AD patients previously fulfilled NMOSD seronegative diagnostic criteria. 9 , 10 However, MOG-AD is currently considered a separate nosologic entity pathogenetically distinct from both anti-Aquaporin4-antibodies (AQP4-ab)-positive NMOSD and from MS. 8 Short- and long-term prognosis in patients presenting NMOSD or MOG-AD is uncertain, and will depend on individual case characteristics as well as several other variables including: place of residence and/or ethnicity of the patient, disease severity, type of debut symptom, treatment given or strategies proposed and time to treatment onset, among others. 1 – 8 As a consequence, acute treatment response rates in both diseases should be evaluated separately.…”

Section: Introductionmentioning

confidence: 99%

“… 1 – 8 As a consequence, acute treatment response rates in both diseases should be evaluated separately. 8 – 10 …”

Section: Introductionmentioning

confidence: 99%

“…Although there are no NMOSD and MOG-AD prevalence data in Argentina, epidemiologic information about MS/NMOSD ratio (21:1) and percentage of MOG-AD in AQP4-ab-negative NMOSD patients (27%) were recently published. 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina

Contentti¹,

López²,

Pettinicchi³

et al. 2021

Multiple Sclerosis Journal - Experimental, Translational and Cl

Self Cite

View full text Add to dashboard Cite

We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optica spectrum disorders (NMOSD) attacks (frequency, types, and response). Methods Retrospective study. Data on patient demographic, clinical and radiological findings, and administered treatments were collected. Remission status (complete [CR], partial [PR], no remission [NR]), based on changes in the EDSS score was evaluated before treatment, during attack, and at 6 months. CR was analyzed with a generalized estimating equations (GEEs) model. Results A total of 131 patients (120 NMOSD and 11 myelin oligodendrocyte glycoprotein-antibody-associated diseases [MOGAD]), experiencing 262 NMOSD-related attacks and receiving 270 treatments were included. High-dose steroids (81.4%) was the most frequent treatment followed by plasmapheresis (15.5%). CR from attacks was observed in 47% (105/223) of all treated patients. During the first attack, we observed CR:71.2%, PR:16.3% and NR:12.5% after the first course of treatment. For second, third, fourth, and fifth attacks, CR was observed in 31.1%, 10.7%, 27.3%, and 33.3%, respectively. Remission rates were higher for optic neuritis vs. myelitis (p < 0.001). Predictor of CR in multivariate GEE analysis was age in both NMOSD (OR = 2.27, p = 0.002) and MOGAD (OR = 1.53, p = 0.03). Conclusions This study suggests individualization of treatment according to age and attack manifestation. The outcome of attacks was generally poor.

show abstract

Section: Discussionmentioning

confidence: 87%